ECE2020 ePoster Presentations Diabetes, Obesity, Metabolism and Nutrition (142 abstracts)
Evaluation of liver fibrosis in patients with diabesity
Elena González Arnáiz 1 , Begoña Pintor De la Maza 1 , Lucía González Roza 1 , Beatriz Ramos Bachiller 1 , Raisa Quiñones Castro 2 , Diana Ariadel Cobo 1 , David Barajas Galindo 1 , Ana Urioste Fondo 1 , María Ballesteros Pomar 1 & Isidoro Cano Rodriguez 1
1Centre Assistencial Universitary León, Endocrinology and Nutrition, León, Spain; 2Centre Assistencial Universitary León, Digestive Service, León, Spain
Background: NAFLD(non–alcoholic fatty liver disease) includes; non–alcoholic fatty liver(NAFL), non–alcoholic steatohepatitis (NASH) and its complications (fibrosis, cirrhosis and hepatocellular carcinoma). These diseases are currently the most common cause of liver disease in western countries, due to the obesity and DM2 epidemic. There are scores that determine the risk of liver fibrosis in a non–invasive way.
Aims: To determine the prevalence of liver fibrosis diagnosed by FIB4 score, NAFLD fibrosis score and Hepamet fibrosis score in patients with morbid obesity. To evaluate differences in the risk of fibrosis in patients with morbid obesity with or without DM2.
Methods: Cross–sectional observational study of a sample of 95 high–risk obesity patients. Anthropometric variables (weight, size and BMI), analytical variables (glucose, insulin, AST, ALT, albumin and platelets) and non–invasive markers of liver fibrosis (FIB4, NAFLD, Hepamet) were collected. The risk of fibrosis was compared with the presence or absence of DM2.
Results: 95 patients; 73.7% are women and 24.2% had DM2. Mean age 44.22 (DE 8.34) years, weight 122.4 (RIC 84) Kg, BMI 45.82 (DE5.22) kg/m2. 94.7% of patients have FIB4 <1.30 (without fibrosis or mild fibrosis); 3.2% FIB4 1.30–2.67 (undetermined) and 2.1% FIB4 > 2.67 (advanced fibrosis). 28.4% of patients have NAFLD <–1.45 (without fibrosis or mild fibrosis), 65.3% NAFLD –1.45–0.675 (grey area) and 6.3% NAFLD > 0.675 (advanced fibrosis). 85.1% of patients have Hepamet <0.12 (without fibrosis or mild fibrosis), 9.6% Hepamet 0.12–0.24 (Grey area) and 5.3% Hepamet >0.24 (advanced fibrosis). The risk scores for fibrosis in patients with obesity and DM2 are reflected in Table 1.
| SCORES | Diabetes | No diabetes | P | ||
| NAFLD | Without fibrosis or mild fibrosis | 4, 3 % | 36, 1 % | << 0, 001 | |
| Grey area | 78, 3 % | 61, 1 % | |||
| Advanced fibrosis | 17, 4 % | 2, 8 % | |||
| Total | 100 % | 100 % | |||
| FIB4 | Without fibrosis or mild fibrosis | 95, 7 % | 94, 4 % | 0, 34 | |
| Undetermined | 4, 3 % | 2, 8 % | |||
| Advanced fibrosis | 0 % | 2, 8 % | |||
| Total | 100 % | 100 % | |||
| Hepamet | No fibrosis o leve | 45, 5 % | 97, 2 % | < 0, 001 | |
| Grey area | 36, 4 % | 1, 4 % | |||
| Advanced fibrosis | 18, 2 % | 1, 4 % | |||
| Total | 100 % | 100 % |
Conclusions: There is a high prevalence of liver fibrosis in patients with morbid obesity. Patients with obesity and DM2 have a higher risk of fibrosis estimated with NAFLD and Hepamet fibrosis score. In patients with obesity, DM2, or other risk factors, the risk of liver fibrosis should be evaluated as it may condition the long–term prognosis.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more